BTRX-246040

BTRX-246040

Clinical data
Other names	BTRX-246040
Routes of administration	By mouth
Legal status
Legal status	Investigational
Identifiers
IUPAC name [2-[4-[(2-chloro-4,4-difluoro-spiro[5H-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methyl-pyrazol-1-yl]-3-pyridyl]methanol
JSmol)	Interactive image
SMILES Cc1c(cn(n1)c2c(cccn2)CO)CN3CCC4(CC3)c5c(cc(s5)Cl)C(CO4)(F)F
InChI InChI=1S/C22H23ClF2N4O2S/c1-14-16(11-29(27-14)20-15(12-30)3-2-6-26-20)10-28-7-4-21(5-8-28)19-17(9-18(23)32-19)22(24,25)13-31-21/h2-3,6,9,11,30H,4-5,7-8,10,12-13H2,1H3 Key:NKQHBJNRBKHUQR-UHFFFAOYSA-N

BTRX-246040, also known as LY-2940094, is a potent and selective nociceptin receptor antagonist which is under development by BlackThorn Therapeutics and Eli Lilly for the treatment of major depressive disorder (MDD).^[1][2][3] It has demonstrated proof-of-concept clinical efficacy for depression.^[4] As of 2017, it is in phase II clinical trials for the treatment of MDD.^[1][2][3] It was also under investigation for the treatment of alcoholism, and similarly reached phase II clinical studies for this indication, but development was discontinued.^[1]

See also

• List of investigational antidepressants
• J-113,397
• JTC-801
• SB-612,111

References